BMJ Best Practice

参考文献

关键文献

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.

Bandelow B, Sher L, Bunevicius R, et al; WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012 Jun;16(2):77-84.

Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019 Feb 23;393(10173):768-77.

参考文章

1.  American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.

2.  World Health Organization. International classification of diseases, tenth revision. 2010 [internet publication].

3.  Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994 Jan;51(1):8-19.

4.  Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol. 2005 Aug;15(4):445-52.

5.  Alonso J, Angermeyer MC, Bemert S, et al. 12-month comorbidity and associated factors in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;(420):28-37.

6.  Nabavi B, Mitchell AJ, Nutt D. A lifetime prevalence of comorbidity between bipolar affective disorder and anxiety disorders: a meta-analysis of 52 interview-based studies of psychiatric population. EBioMedicine. 2015 Sep 8;2(10):1405-19.

7.  Goldstein-Piekarski AN, Williams LM, Humphreys K. A trans-diagnostic review of anxiety disorder comorbidity and the impact of multiple exclusion criteria on studying clinical outcomes in anxiety disorders. Transl Psychiatry. 2016 Jun 28;6(6):e847.

8.  Alonso J, Lepine JP. Overview of key data from the European Study of the Epidemiology of Mental Disorders. J Clin Psychiatry. 2007;68(suppl 2):3-9.

9.  Oakley-Browne M, Wells E, Scott K, et al. Te rau hinengaro: the New Zealand mental health survey. 2006 [internet publication].

10.  Pigott T. Gender differences in the epidemiology and treatment of anxiety disorders. J Clin Psychiatry. 1999;60 Suppl 18:4-15.

11.  Creighton AS, Davison TE, Kissane DW. The prevalence of anxiety among older adults in nursing homes and other residential aged care facilities: a systematic review. Int J Geriatr Psychiatry. 2016 Jun;31(6):555-66.

12.  Dennis CL, Falah-Hassani K, Shiri R. Prevalence of antenatal and postnatal anxiety: systematic review and meta-analysis. Br J Psychiatry. 2017 May;210(5):315-23.

13.  Remes O, Brayne C, van der Linde R, et al. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain Behav. 2016 Jun 5;6(7):e00497.

14.  Judd LL, Kessler RC, Paulus MP, et al. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand Suppl. 1998;393:6-11.

15.  Andrews G, Peters L, Guzman AM, et al. A comparison of two structured diagnostic interviews: CIDI and SCAN. Aust N Z J Psychiatry. 1995 Mar;29(1):124-32.

16.  Brantley PJ, Mehan DJ Jr, Ames SC, et al. Minor stressors and generalized anxiety disorders among low income patients attending primary care clinics. J Nerv Ment Dis. 1999 Jul;187(7):435-40.

17.  Lau AW, Edelstein BA, Larkin KT. Psychophysiological arousal in older adults: a critical review. Clin Psychol Rev. 2001 Jun;21(4):609-30.

18.  Brown ES, Fulton MK, Wilkeson A, et al. The psychiatric sequelae of civilian trauma. Compr Psychiatry. 2000 Jan-Feb;41(1):19-23.

19.  Möller EL, Nikolić M, Majdandžić M, et al. Associations between maternal and paternal parenting behaviors, anxiety and its precursors in early childhood: a meta-analysis. Clin Psychol Rev. 2016 Apr;45:17-33.

20.  Hawker DSJ, Boulton MJ. Twenty years' research on peer victimization and psychosocial maladjustment: a meta-analytic review of cross-sectional studies. J Child Psychol Psychiatry. 2000 May;41(4):441-55.

21.  Hettema JM, Neale NC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry. 2001 Oct;158(10):1568-78.

22.  Middeldorf CM, Cath CD, Van Dyck R, et al. The co-morbidity of anxiety and depression in the perspective of genetic epidemiology: a review of twin and family studies. Psychol Med. 2005 May;35(5):611-24.

23.  Gottschalk MG, Domschke K. Genetics of generalized anxiety disorder and related traits. Dialogues Clin Neurosci. 2017 Jun;19(2):159-68.

24.  Nutt DJ. Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry. 2001;62 Suppl 11:22-7.

25.  Krystal JH, D'Souza DC, Sanacora G, et al. Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders. Med Clin North Am. 2001 May;85(3):559-77.

26.  Bremner JD, Licinio J, Darnell A, et al. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry. 1997 May;154(5):624-9.

27.  Saletu-Zyhlarz G, Saletu B, Anderer P, et al. Nonorganic insomnia in generalized anxiety disorder. 1. Controlled studies on sleep, awakening and daytime vigilance utilizing polysomnography and EEG mapping. Neuropsychobiology. 1997;36(3):117-29.

28.  Grigsby AM, Anderson RJ, Freedland KE, et al. Prevalence of anxiety in adults with diabetes: a systematic review. J Psychosom Res. 2002 Dec;53(6):1053-60.

29.  Rogers MP, White K, Warshaw MG, et al. Prevalence of medical illness in patients with anxiety disorders. Int J Psychiatry Med. 1994;24(1):83-96.

30.  Fricchione G. Generalized anxiety disorder. N Engl J Med. 2004 Aug 12;351(7):675-82.

31.  Pary R, Matuschka PR, Lewis S. Generalized anxiety disorder. South Med J. 2003 Jun;96(6):581-6.

32.  Gale C, Oakley-Browne M. Generalized anxiety disorder. Clin Evid. 2005 Dec;(14):1253-69.

33.  Herr NR, Williams JW Jr, Benjamin S, et al. Does this patient have generalized anxiety or panic disorder?: The Rational Clinical Examination systematic review. JAMA. 2014 Jul 2;312(1):78-84.

34.  Plummer F, Manea L, Trepel D, et al. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016 Mar-Apr;39:24-31.

35.  Andrews G, Bell C, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. Aust N Z J Psychiatry. 2018 Nov;52(12):1109-72.

36.  Pinquart M, Duberstein PR. Treatment of anxiety disorders in older adults: a meta-analytic comparison of behavioral and pharmacological interventions. Am J Geriatr Psychiatry. 2007 Aug;15(8):639-51.

37.  Thorp SR, Ayers CR, Nuevo R, et al. Meta-analysis comparing different behavioral treatments for late-life anxiety. Am J Geriatr Psychiatry. 2009 Feb;17(2):105-15.

38.  Hendriks GJ, Oude Voshaar RC, Keijsers GP, et al. Cognitive-behavioural therapy for late-life anxiety disorders: a systematic review and meta-analysis. Acta Psychiatr Scand. 2008 Jun;117(6):403-11.

39.  Cuijpers P, Cristea IA, Weitz E, et al. The effects of cognitive and behavioural therapies for anxiety disorders on depression: a meta-analysis. Psychol Med. 2016 Dec;46(16):3451-62.

40.  Griffiths KMF, Farrer L, Christensen H. The efficacy of internet interventions for depression and anxiety disorders: a review of randomised controlled trials. Med J Aust. 2010 Jun 7;192(11 suppl):S4-11.

41.  Robinson E, Titov N, Andrews G, et al. Internet treatment for generalized anxiety disorder: a randomized controlled trial comparing clinician vs. technician assistance. PLoS One. 2010 Jun 3;5(6):e10942.

42.  Zalta AK. A meta-analysis of anxiety symptom prevention with cognitive-behavioral interventions. J Anxiety Disord. 2011 Jun;25(5):749-60.

43.  Olthuis JV, Watt MC, Bailey K, et al. Therapist-supported internet cognitive behavioural therapy for anxiety disorders in adults. Cochrane Database Syst Rev. 2016 Mar 12;(3):CD011565.

44.  Hunot V, Churchill R, Silva de Lima M, et al. Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001848.

45.  Knekt P, Lindfors O, Laaksonen MA, et al.; Helsinki Psychotherapy Study Group. Quasi-experimental study on the effectiveness of psychoanalysis, long-term and short-term psychotherapy on psychiatric symptoms, work ability and functional capacity during a 5-year follow-up. J Affect Disord. 2011 Jul;132(1-2):37-47.

46.  Leichsenring F, Salzer S, Jaeger U, et al. Short-term psychodynamic psychotherapy and cognitive-behavioral therapy in generalized anxiety disorder: a randomized, controlled trial. Am J Psychiatry. 2009 Aug;166(8):875-81.

47.  Creswell C, Cruddace S, Gerry S, et al. Treatment of childhood anxiety disorder in the context of maternal anxiety disorder: a randomised controlled trial and economic analysis. Health Technol Assess. 2015 May;19(38):1-184.

48.  Hoge EA, Bui E, Marques L, et al. Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity. J Clin Psychiatry. 2013 Aug;74(8):786-92.

49.  Wong SY, Yip BH, Mak WW, et al. Mindfulness-based cognitive therapy v. group psychoeducation for people with generalised anxiety disorder: randomised controlled trial. Br J Psychiatry. 2016 Jul;209(1):68-75.

50.  Roszkowska J, Geraci SA. Management of insomnia in the geriatric patient. Am J Med. 2010 Dec;123(12):1087-90.

51.  Roy-Byrne P, Veitengruber JP, Bystritsky A, et al. Brief intervention for anxiety in primary care patients. J Am Board Fam Med. 2009 Mar-Apr;22(2):175-86.

52.  Herring MP, O'Connor PJ, Dishman RK. The effect of exercise training on anxiety symptoms among patients: a systematic review. Arch Intern Med. 2010 Feb 22;170(4):321-31.

53.  van Boeijen CA, van Balkom AJ, van Oppen P, et al. Efficacy of self-help manuals for anxiety disorders in primary care: a systematic review. Fam Pract. 2005 Apr;22(2):192-6.

54.  Haug T, Nordgreen T, Öst LG, et al. Self-help treatment of anxiety disorders: a meta-analysis and meta-regression of effects and potential moderators. Clin Psychol Rev. 2012;32:425-445.

55.  Bandelow B, Sher L, Bunevicius R, et al; WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012 Jun;16(2):77-84.

56.  Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019 Feb 23;393(10173):768-77.

57.  Sinclair LI, Christmas DM, Hood SD, et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry. 2009 Jun;194(6):483-90.

58.  Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014 May;28(5):403-39.

59.  Schuurmans J, Comijs H, Emmelkamp PM, et al. Long-term effectiveness and prediction of treatment outcome in cognitive behavioral therapy and sertraline for late-life anxiety disorders. Int Psychogeriatr. 2009 Dec;21(6):1148-59.

60.  Ipser, JC, Stein DJ, Hawkridge S, et al. Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD005170.

61.  Dobson ET, Strawn JR. Pharmacotherapy for pediatric generalized anxiety disorder: a systematic evaluation of efficacy, safety and tolerability. Paediatr Drugs. 2016 Feb;18(1):45-53.

62.  Khan AY, Macaluso M. Duloxetine for the treatment of generalized anxiety disorder: a review. Neuropsychiatr Dis Treat. 2009;5:23-31.

63.  Brawman-Mintzer O, Knapp RG, Rynn M, et al. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clinical Psychiatry. 2006 Jun;67(6):874-81.

64.  Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol. 2006 Oct;9(5):495-505.

65.  de Vries YA, de Jonge P, van den Heuvel E, et al. Influence of baseline severity on antidepressant efficacy for anxiety disorders: meta-analysis and meta-regression. Br J Psychiatry. 2016 Jun;208(6):515-21.

66.  Chessick CA, Allen MH, Thase M, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD006115.

67.  Donnelly K, Bracchi R, Hewitt J, et al. Benzodiazepines, Z-drugs and the risk of hip fracture: a systematic review and meta-analysis. PLoS One. 2017 Apr 27;12(4):e0174730.

68.  Née M, Avalos M, Luxcey A, et al. Prescription medicine use by pedestrians and the risk of injurious road traffic crashes: A case-crossover study. PLoS Med. 2017 Jul 18;14(7):e1002347.

69.  Gale C, Glue P, Guaiana G, et al. Influence of covariates on heterogeneity in Hamilton Anxiety Scale ratings in placebo-controlled trials of benzodiazepines in generalized anxiety disorder: systematic review and meta-analysis. J Psychopharmacol. 2019 Jan 24 [Epub ahead of print].

70.  Petrushevska T, Jakovski Z, Poposka V, et al. Drug-related deaths between 2002 and 2013 with accent to methadone and benzodiazepines. J Forensic Leg Med. 2015 Apr;31:12-8.

71.  Lintzeris N, Nielsen S. Benzodiazepines, methadone and buprenorphine: interactions and clinical management. Am J Addict. 2010 Jan-Feb;19(1):59-72.

72.  Rickels K, Shiovitz TM, Ramey TS, et al. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol. 2012 May;27(3):142-50.

73.  Generoso MB, Trevizol AP, Kasper S, et al. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Int Clin Psychopharmacol. 2017 Jan;32(1):49-55.

74.  Buoli M, Caldiroli A, Serati M. Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder. Expert Opin Drug Metab Toxicol. 2017 Mar;13(3):351-9.

75.  LaLonde CD, Van Lieshout RJ. Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis. J Clin Psychopharmacol. 2011 Jun;31(3):326-33.

76.  Schmitt R, Gazalle FK, Lima MS, et al. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. Braz J Psychiatry. 2005 Mar;27(1):18-24.

77.  Shammas E. Controlled comparison of bromazepam, amitriptyline, and placebo in anxiety-depressive neurosis. Dis Nerv Syst. 1977 Mar;38(3):201-7.

78.  Goldberg HL, Finnery RJ. The use of doxepin in the treatment of symptoms of anxiety neurosis and accompanying depression: a collaborative controlled study. Am J Psychiatry. 1972 Jul;129(1):74-7.

79.  Maneeton N, Maneeton B, Woottiluk P, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2016 Jan 12;10:259-76.

80.  National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management in primary, secondary and community care. Jan 2011 [internet publication].

81.  Batelaan NM, Bosman RC, Muntingh A, et al. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ. 2017 Sep 13;358:j3927.

82.  Mancini M, Perna G, Rossi A, et al. Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature. Expert Opin Pharmacother. 2010 May;11(7):1167-81.

83.  Youssef NA, Rich CL. Does acute treatment with sedatives/hypnotics for anxiety in depressed patients affect suicide risk? A literature review. Ann Clin Psychiatry. 2008 Jul-Sep;20(3):157-69.

84.  Pollack MH, Roy-Byrne PP, Van Ameringen M, et al. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry. 2005 Nov;66(11):1401-8.

85.  Guidelines and Protocols Advisory Committee; British Columbia Medical Association. Anxiety and depression in children and youth – diagnosis and treatment. Mar 2010 [internet publication].

86.  Griffiths KM. SPARX computerised CBT is as effective as usual care for mild-to-moderate depression in help seeking adolescents. Evid Based Ment Health. 2012 Nov;15(4):90.

87.  Wang Z, Whiteside SPH, Sim L, et al. Comparative effectiveness and safety of cognitive behavioral therapy and pharmacotherapy for childhood anxiety disorders: a systematic review and meta-analysis. JAMA Pediatr. 2017 Nov 1;171(11):1049-56.

88.  Strawn JR, Mills JA, Sauley BA, et al. The impact of antidepressant dose and class on treatment response in pediatric anxiety disorders: a meta-analysis. J Am Acad Child Adolesc Psychiatry. 2018 Apr;57(4):235-44.

89.  Gale CK, Millichamp J. Generalised anxiety disorder in children and adolescents. BMJ Clin Evid. 2016 Jan 13;2016.

90.  McAllister-Williams RH, Baldwin DS, Cantwell R, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol. 2017 May;31(5):519-52.

91.  Massachusetts General Hospital Center for Women’s Mental Health. Psychiatric disorders during pregnancy. 2013 [internet publication].

92.  Glasheen C, Richardson GA, Fabio A. A systematic review of the effects of postnatal maternal anxiety on children. Arch Womens Ment Health. 2010 Feb;13(1):61-74.

93.  Yonkers KA, Gilstad-Hayden K, Forray A, et al. Association of panic disorder, generalized anxiety disorder, and benzodiazepine treatment during pregnancy with risk of adverse birth outcomes. JAMA Psychiatry. 2017 Nov 1;74(11):1145-52.

94.  Rai D, Lee B, Dalman C, et al. Antidepressants during pregnancy and autism in offspring: population based cohort study. BMJ. 2017 Jul 19;358:j2811.

95.  Kaplan YC, Keskin-Arslan E, Acar S, et al. Maternal SSRI discontinuation, use, psychiatric disorder and the risk of autism in children: a meta-analysis of cohort studies. Br J Clin Pharmacol. 2017 Dec;83(12):2798-806.

96.  Brown HK, Hussain-Shamsy N, Lunsky Y, et al. The association between antenatal exposure to selective serotonin reuptake inhibitors and autism: a systematic review and meta-analysis. J Clin Psychiatry. 2017 Jan;78(1):e48-58.

97.  Ray S, Stowe ZN. The use of antidepressant medication in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2014 Jan;28(1):71-83.

98.  Andrews G, Hobbs MJ. The effect of the draft DSM-5 criteria for GAD on prevalence and severity. Aust N Z J Psychiatry. 2010 Sep;44(9):784-90.

99.  Covin R, Ouimet AJ, Seeds PM, et al. A meta-analysis of CBT for pathological worry among clients with GAD. J Anxiety Disord. 2008;22(1):108-16.

100.  Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol. 2010 Apr;13(3):305-20.

101.  Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011 Sep 28;306(12):1359-69.

102.  Albert U, Carmassi C, Cosci F, et al. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. Int Clin Psychopharmacol. 2016 Sep;31(5):249-58.

103.  Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2003;(1):CD003383.

104.  Pittler MH, Ernst E. Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther. 2003 Sep 1;18(5):451-71.

105.  Savage KM, Stough CK, Byrne GJ, et al. Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial. Trials. 2015 Nov 2;16:493.

106.  Kessler RC, DuPont RL, Berglund P, et al. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry. 1999 Dec;156(12):1915-23.

107.  Hall WD, Mant A, Mitchell PB, et al. Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ. 2003 May 10;326(7397):1008.

108.  Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med. 2000 Dec 28;343(26):1942-50.

109.  Davidson JR, Wittchen HU, Llorca PM, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2008 Sep;18(9):673-81.

110.  Feltner D, Wittchen HU, Kavoussi R, et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol. 2008 Jan;23(1):18-28.

使用此内容应接受我们的免责声明